Faeth Presents Updated Preclinical Data at ESMO, including First-Ever Head-to-Head Characterization of PIKTOR against GedatolisibBusiness Wire · 3 days ago
Faeth Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Business Wire · 4 days ago
Faeth to Present Preclinical Data on PIKTOR in HR+/HER2- Breast Cancer Models at ESMO 2026Business Wire · Oct 19, 2026
Sensei Biotherapeutics (NASDAQ:FTH) Shares Gap Up – Here’s What HappenedDefense World · Oct 18, 2026
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of DirectorsBusiness Wire · Sep 17, 2026
Faeth Therapeutics Appoints Karen Vousden, Ph.D., to Board of DirectorsGuruFocus · Sep 17, 2026Faeth Therapeutics, Inc. is a clinical-stage biotechnology company focused on improving outcomes for cancer patients through multi-node inhibition of critical oncogenic pathways. [28, 70] The company's lead program, PIKTOR, is an investigational all-oral combination therapy targeting the PI3K/AKT/mTOR pathway. [28, 70]
| Date | Est. | Actual | |
|---|---|---|---|
| Aug 4, 2026 | -$2.64 | -$2.84 | Miss |
| May 15, 2026 | -$0.62 | -$131.45 | Miss |
| Mar 30, 2026 | -$4.81 | -$3.74 | Beat |
| Nov 14, 2025 | -$4.11 | -$3.62 | Beat |
| Aug 5, 2025 | -$6.20 | -$3.91 | Beat |
| May 6, 2025 | -$4.20 | -$5.40 | Miss |